EARLY USE OF RITUXIMAB AS A FIRST LINE THERAPY IN PEDIATRIC ONSET MULTIPLE SCLEROSIS

Pediatric onset multiple sclerosis (POMS) is an increasingly recognized disorder with a significant morbidity. It is a challenge to select a medication for pediatric patients to maintain remission, considering the young age of onset, disease course, side effects and adherence to treatment. Here we present two cases of pediatric multiple sclerosis with a very aggressive course and who were eventually started on Rituximab as Disease Modifying Treatment (DMT).Rituximab is a safe alternative to prevent frequent relapses and can be considered as a first line disease modifying therapy in children.